CVR Medical Aktie - CVM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

0,015

Gebot

0,015

Fragen

0,02

Volumen

0,00 Tagesbereich 0,00

0,015 52-Wochen-Bereich 0,015

Handelsende

0,015

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology VIENNA, Va., Feb. 22...

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

Company Ends Quarter in Strongest Financial Condition Ever VIENNA, Va., Feb. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM...

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced that Geert Kersten, Chief Executive Officer, will...

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage oncology company and a developer of vaccines...

CEL-SCI Corporation Announces 2009 Financial Results

Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion VIENNA, Va., Jan. 13...

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

Facility Is Also Expected to Generate Revenue Through Contract Manufacturing VIENNA, Va., Jan. 11 /PRNewswire-FirstCall/ -- CEL-SCI Corporation...

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

VIENNA, Va., Dec. 1 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines...

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

VIENNA, Va., Nov. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention...

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1 HOSPITALIZED PATIENTS VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/...

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0.015	0.015	0.015	0	0	CS
4	0	0	0.015	0.015	0.015	0	0	CS
12	0	0	0.015	0.015	0.015	0	0	CS
26	0	0	0.015	0.015	0.015	0	0	CS
52	0	0	0.015	0.015	0.015	0	0	CS
156	-0.01	-40	0.025	0.03	0.015	1140	0.02194414	CS
260	-0.185	-92.5	0.2	0.2	0.015	54488	0.04319827	CS

CVM - Frequently Asked Questions (FAQ)

What is the current CVR Medical share price?

The current share price of CVR Medical is $ 0,015

What is the 1 year trading range for CVR Medical share price?

CVR Medical has traded in the range of $ 0,015 to $ 0,015 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AAAAAuralite Investments Inc	$ 0,265 (0,00%)	0
AAA.PFirst Tidal Acquisition Corp	$ 0,055 (0,00%)	0
AAAlba Minerals Ltd	$ 0,03 (0,00%)	0
A.HArmor Minerals Inc	$ 0,355 (0,00%)	0
AArmor Minerals Inc	$ 0,45 (0,00%)	0
AAAAAuralite Investments Inc	$ 0,265 (0,00%)	0
AAA.PFirst Tidal Acquisition Corp	$ 0,055 (0,00%)	0
AAAlba Minerals Ltd	$ 0,03 (0,00%)	0
A.HArmor Minerals Inc	$ 0,355 (0,00%)	0
AArmor Minerals Inc	$ 0,45 (0,00%)	0
AAAAAuralite Investments Inc	$ 0,265 (0,00%)	0
AAA.PFirst Tidal Acquisition Corp	$ 0,055 (0,00%)	0
AAAlba Minerals Ltd	$ 0,03 (0,00%)	0
A.HArmor Minerals Inc	$ 0,355 (0,00%)	0
AArmor Minerals Inc	$ 0,45 (0,00%)	0

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CVR Medical Corporation (CVM)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

CVM Neueste Nachrichten

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

CEL-SCI Corporation Announces 2009 Financial Results

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

CVM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CVR Medical Corporation (CVM) Börsenkurse

CVR Medical Corporation (CVM)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

CVM Neueste Nachrichten

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

CEL-SCI Corporation Announces 2009 Financial Results

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

CVM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen